The Thailand Food and Drug Administration approved Antengene's (HKG:6996) new drug application for its selinexor drug, according to a Monday filing with the Hong Kong Stock Exchange.
The approvals are for the combination of selinexor with bortezomib and dexamethasone for multiple myeloma patients with at least one prior therapy.
The drug is also indicated for combination with dexamethasone for multiple myeloma patients with at least four prior therapies and resistance to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, the filing said.
Shares closed 4% higher during Monday's trading.
Price (HKD): $0.57, Change: $+0.020, Percent Change: +3.64%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.